Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
about
Allopurinol for chronic gout2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaTreatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implicationsUntargeted plasma metabolite profiling reveals the broad systemic consequences of xanthine oxidoreductase inactivation in miceAllopurinol: insights from studies of dose-response relationships.Chronic kidney disease in gout in a managed care settingThe efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney diseaseRemembering the forgotten non-communicable diseases.Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.Impaired response or insufficient dosage? Examining the potential causes of "inadequate response" to allopurinol in the treatment of gout[The etiology and management of gout].Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists.The pharmacokinetics of oxypurinol in people with gout.Latest evidence on gout management: what the clinician needs to knowPredicting allopurinol response in patients with goutModifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare systemColchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.Poorly controlled gout: who is doing poorly?Critical appraisal of the role of pegloticase in the management of gout.Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study.Diabetes and gout: efficacy and safety of febuxostat and allopurinol.Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.The challenges of gout management in the elderly.Recent advances in management of gout.Gout and organ transplantation.Gout and its comorbidities: implications for therapy.Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.Safety and efficacy of allopurinol in chronic kidney disease.Optimizing current treatment of gout.Pharmacokinetics considerations for gout treatments.Urate-lowering therapy: current options and future prospects for elderly patients with gout.Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review.Advances in pharmacotherapy for the treatment of gout.Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative.Allopurinol hypersensitivity: investigating the cause and minimizing the risk.Current and future therapies for gout.Management of Gout and Hyperuricemia in CKD.
P2860
Q24193107-3914ADA0-0C96-45D7-AD65-53F5D14077F0Q24612292-7EE9BDAB-7DDE-48B4-88F1-76925F63851AQ26738948-9D9AC0FE-A25E-41F3-8A1C-B87D5B7E4B7FQ28480520-74B20233-58E7-44F0-A82A-E68C50C2E3CFQ30240163-8D7E0DDD-2F00-419B-B711-F23BAD140345Q33980619-3D4EE18D-5695-47D6-AA9D-AEAE17806DC8Q34204854-6E74DA01-B1EC-4739-9457-D55D5D94E23EQ34317722-28265D7F-9DF8-42FE-A263-22502CD6B7A1Q34394682-504861DB-86ED-4B75-A987-D246698FA143Q34415029-83C8B987-ECCD-4EC7-914A-92A169684929Q34476295-5ACC44C0-6D87-4759-947E-79A8C9DE7004Q34636225-BF5E8DCE-DC4A-4B32-B153-C766B57CD03AQ35528880-548A45C2-B399-4E74-92E5-B0B1508D7443Q35746133-3E8600D6-6E03-4D86-A92A-040476C24A0EQ36336035-F0B6DB2E-62C1-4954-A7D2-DF7E0E8801DFQ36515484-F2DCA8E0-3EA2-4753-89E6-35117258102FQ36802064-609604F7-72C7-4DAC-AF43-FEDE96E85022Q37041741-FD224584-6B07-4EE1-9DD5-1085D072BFADQ37070180-293432A5-D86F-47BD-84CB-754C1E170813Q37195376-0DAC05C3-947F-471F-B9C5-9C4F203E5BBBQ37301152-1726385F-831D-48E9-88B1-06D900AE36A3Q37353448-58834F66-5C9C-4EC2-8782-B82AF92649C1Q37516253-32F4473E-8E79-4832-9A71-DB5CFE5EBB14Q37518810-A99B4B16-F917-4940-9296-C77CFF7BA686Q37553140-F4671B44-2E75-4946-BBA9-D0E7A7D631DFQ37910891-E1BC2528-190B-4912-8D4F-90659F979803Q37971360-8E998243-222F-4A3D-8284-8BA8AE3C030BQ37976996-E7FA8B2C-D189-45B4-96A0-92C9A82BA3C7Q38040777-5F98821E-9E6F-4059-94F2-EF393A70CC88Q38123116-1FE7572B-67B3-41BC-8006-847AB6D2E17BQ38164653-836FFD9B-3F06-45A1-B1F1-761EBF27C25EQ38194896-B30DD1A6-5670-44F0-9616-1AEDC0DA3438Q38210284-28F35132-EB9D-477A-92AB-17C1EE7A9C9EQ38254304-D82ECDCF-5886-4CF1-BF07-C8E0C4FA5FCDQ38268302-779609EB-9FCB-4D86-954A-CAE2D2289A4BQ38303416-A7D40A9B-196F-4A80-871C-9658EAE2F94EQ38425896-16FC6F33-5F28-432A-938A-022453C2B898Q38594891-34ED18B2-97CD-4F9A-B4EE-5AD5D202D38CQ38660829-A4AA48B2-5810-4473-ACB3-3EBDA3781B50Q38812962-DD820839-DF1E-4506-A094-16BFA5DA63BC
P2860
Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Using allopurinol above the do ...... g those with renal impairment.
@en
Using allopurinol above the do ...... g those with renal impairment.
@nl
type
label
Using allopurinol above the do ...... g those with renal impairment.
@en
Using allopurinol above the do ...... g those with renal impairment.
@nl
prefLabel
Using allopurinol above the do ...... g those with renal impairment.
@en
Using allopurinol above the do ...... g those with renal impairment.
@nl
P2093
P356
P1476
Using allopurinol above the do ...... ng those with renal impairment
@en
P2093
Christopher Frampton
Jill James
John L O'Donnell
Lisa K Stamp
Peter T Chapman
P304
P356
10.1002/ART.30119
P577
2011-02-01T00:00:00Z